Literature DB >> 17323937

From five- to six-membered rings: 3,4-diarylquinolinone as lead for novel p38MAP kinase inhibitors.

Christian Peifer1, Katrin Kinkel, Mohammed Abadleh, Dieter Schollmeyer, Stefan Laufer.   

Abstract

In this study we describe the design, synthesis, and biological evaluation of 3-(4-fluorophenyl)-4-pyridin-4-ylquinoline-2(1H)-one (5) as a new inhibitor of MAPK with a p38alphaMAPK IC50 of 1.8 muM. By keeping the common vicinal pyridine/4-F-phenyl pharmacophore, such as in prototypical imidazole 20 or isoxazole 13 but in 5 connected to the six-membered quinoline core, we were particularly interested in comparing biological activity, details of molecular geometry, and different binding modes of these compounds. Compounds 20 and 13 were active both in the p38alpha- and JNK3-assay, whereas 5 was selective for p38alpha, with no JNK3 inhibition. By comparing the X-ray structures of the compounds, we found a significantly larger distance between the pyridine and the 4-F-phenyl moiety in five-membered core structures relevant for ligand-protein interactions. Molecular modeling studies support the results based on differences in the ATP pockets of p38alpha and JNK3. Because most five-membered core based p38alpha inhibitors show also activity for JNK3, compound 5 is an interesting lead for selective p38alpha inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17323937     DOI: 10.1021/jm061097o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

Review 1.  Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D).

Authors:  Pengfei Xu; Chiara Ianes; Fabian Gärtner; Congxing Liu; Timo Burster; Vasiliy Bakulev; Najma Rachidi; Uwe Knippschild; Joachim Bischof
Journal:  Gene       Date:  2019-07-31       Impact factor: 3.688

2.  Methyl 4-[5-(4-fluoro-phen-yl)-4-(pyridin-4-yl)-1H-imidazol-2-ylsulfan-yl]butanoate.

Authors:  Pierre Koch; Christiane Bäuerlein; Dieter Schollmeyer; Stefan Laufer
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-06-07

3.  3D-QSAR and molecular docking studies on fused pyrazoles as p38α mitogen-activated protein kinase inhibitors.

Authors:  Ping Lan; Zhi-Jian Huang; Jun-Rong Sun; Wei-Min Chen
Journal:  Int J Mol Sci       Date:  2010-09-17       Impact factor: 5.923

4.  1-(4-Chloro-phen-yl)-3-(2-meth-oxy-anilino)propan-1-one.

Authors:  Ligia Llovera; Pavel Anzenbacher; Simón E López; Teresa González
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-01-12

5.  Investigation on biological activities of anthranilic acid sulfonamide analogs.

Authors:  Sutanun Doungsoongnuen; Apilak Worachartcheewan; Ratchanok Pingaew; Thummaruk Suksrichavalit; Supaluk Prachayasittikul; Somsak Ruchirawat; Virapong Prachayasittikul
Journal:  EXCLI J       Date:  2011-10-07       Impact factor: 4.068

6.  Optimized 4,5-Diarylimidazoles as Potent/Selective Inhibitors of Protein Kinase CK1δ and Their Structural Relation to p38α MAPK.

Authors:  Jakob Halekotte; Lydia Witt; Chiara Ianes; Marc Krüger; Mike Bührmann; Daniel Rauh; Christian Pichlo; Elena Brunstein; Andreas Luxenburger; Ulrich Baumann; Uwe Knippschild; Joachim Bischof; Christian Peifer
Journal:  Molecules       Date:  2017-03-24       Impact factor: 4.411

7.  Lead generation and optimization based on protein-ligand complementarity.

Authors:  Koji Ogata; Tetsu Isomura; Shinji Kawata; Hiroshi Yamashita; Hideo Kubodera; Shoshana J Wodak
Journal:  Molecules       Date:  2010-06-17       Impact factor: 4.411

8.  cRGDyK-modified procaine liposome inhibits the proliferation and motility of glioma cells via the ERK/p38MAPK pathway.

Authors:  Dedong Li; Jie Gao; Chenyi Yang; Bo Li; Jian Sun; Mingdong Yu; Ying Wang; Haiyun Wang; Yuechun Lu
Journal:  Exp Ther Med       Date:  2021-06-09       Impact factor: 2.447

9.  Marine derived hamacanthins as lead for the development of novel PDGFRβ protein kinase inhibitors.

Authors:  Boris Pinchuk; Eugen Johannes; Sheraz Gul; Joachim Schlosser; Christoph Schaechtele; Frank Totzke; Christian Peifer
Journal:  Mar Drugs       Date:  2013-08-26       Impact factor: 5.118

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.